UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) |
July 30, 2015 |
NAVIDEA BIOPHARMACEUTICALS, INC. |
(Exact name of registrant as specified in its charter) |
Delaware |
001-35076 |
31-1080091 |
(State or other jurisdiction |
(Commission |
(IRS Employer |
of incorporation) |
File Number) |
Identification No.) |
5600 Blazer Parkway, Suite 200, Dublin, Ohio |
43017 |
(Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including area code |
(614) 793-7500 |
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
| Item 2.02 | Results of Operations and
Financial Condition. |
On July 30, 2015, the Company issued a press
release regarding its consolidated financial results for the second quarter of 2015. A copy of the Company’s July 30, 2015
press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in Item 2.02 of
this Current Report on Form 8-K, including exhibit 99.1 attached hereto, shall not be treated as “filed” for purposes
of the Securities Exchange Act of 1934, as amended.
| Item 9.01 | Financial Statements and
Exhibits. |
Exhibit |
|
Number |
Exhibit Description |
|
|
99.1 |
Press
Release, dated July 30, 2015, entitled “Navidea Reports Second Quarter 2015 Financial Results; Reiterates 2015 Lymphoseek®
Revenue Guidance.” |
Statements contained or incorporated by
reference in this Current Report on Form 8-K which relate to other than strictly historical facts, such as statements about the
Company’s plans and strategies, expectations for future financial performance, new and existing products and technologies,
and markets for the Company’s products, are forward-looking statements. The words “believe,” “expect,”
“anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements
that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could
cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited
to, the Company’s continuing operating losses, uncertainty of market acceptance, reliance on third party manufacturers, accumulated
deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition,
limited marketing and manufacturing experience, and other risks detailed in the Company’s most recent Annual Report on Form
10-K and other filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly
update or revise any forward-looking statements.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
Navidea Biopharmaceuticals, Inc. |
|
|
|
|
|
|
|
|
|
Date: August 5, 2015 |
By: |
/s/ Brent L. Larson |
|
|
|
Brent L. Larson, Executive Vice President and Chief Financial Officer |
|
|
|
|
|
Exhibit 99.1
FOR IMMEDIATE RELEASE
Navidea Reports Second Quarter 2015 Financial Results;
Reiterates
2015 Lymphoseek® Revenue Guidance
DUBLIN OHIO, July 30, 2015 - Navidea Biopharmaceuticals,
Inc. (NYSE MKT: NAVB), today announced financial results for the second quarter of 2015. Navidea
reported total revenue for the second quarter of 2015 of $2.9 million, including Lymphoseek® (technetium
Tc 99m tilmanocept) injection sales revenue of $2.0 million. The net loss from operations was $3.8 million and the
net loss attributable to common stockholders was $9.7 million.
“During the first half of this year
we successfully undertook a strategy to transform the Company and we have been executing to that plan,” commented Rick Gonzalez,
Navidea’s President and CEO. “We deployed a new commercial strategy, overhauled the Lymphoseek brand plan reflective
of the brand’s clinical value proposition, optimized operational efficiencies across the organization, strengthened our financial
position and made progress in a cost-effective fashion to expand our development pipeline of both imaging and therapeutic programs.
Today we are on a clear path, whereby our revenue growth is quickly converging with our reduced operating expenses, getting us
closer to the goal of achieving cash flow breakeven in the first quarter of next year.”
Specific events and milestones achieved since the beginning
of the second quarter include the following:
Commercial
| - | Achieved sequential
quarter-on-quarter Lymphoseek revenue growth and continued improvement in key performance indicators; |
| - | Fully deployed a Lymphoseek-dedicated
field force mid-second quarter; |
| - | Exercised pricing leverage,
as per plan, resulting in a 39% Lymphoseek price increase beginning July 31st; |
| - | Reported positive Lymphoseek
comparative results from an injection site pain study in breast cancer presented at the 2015 Society of Nuclear Medicine and Molecular
Imaging annual meeting; |
Lymphoseek Lifecycle Management
| - | Awarded
NIH grants to explore new applications of the Manocept™ platform for cardiovascular disease and rheumatoid arthritis (RA)
totaling up to $2.0 million; |
| - | Received
confirmation of continued development funding under part 2 of a previously awarded NIH grant for Lymphoseek in cervical cancer
totaling $1.5 million; |
| - | Reported
clinical imaging data demonstrating Tc 99m tilmanocept localizes in Kaposi’s sarcoma (KS) tumor lesions including brain
lesions; |
| - | Verified
Manocept CD206-targeting mechanism of action with publication in peer-reviewed Journal of Immunology providing clear
clinical differentiation from other non-targeted agents and showing future potential
for the delivery of therapeutics for cancer and other macrophage-dependent diseases; |
Operational & Financial
| - | Reduced cash burn by
over 40% for the first half of 2015 compared to the first half of 2014; |
| - | Secured
approximately $18 million in additional net capital; |
| - | Completed the divestiture
of the Company’s investigational imaging agent for the detection of Parkinson’s disease; |
| - | Continued partnering/divestiture
efforts for the Company’s investigational imaging agent, NAV4694, for the detection of amyloid
plaques in Alzheimer’s disease; |
NAVIDEA BIOPHARMACEUTICALS
Page | 2
Therapeutic & Diagnostic Development Pipeline
| - | Reported data
demonstrating that a Manocept-Doxorubicin (MT-1001) conjugate selectively targets tumor-associated macrophages and destroys the
cells through an apoptotic mechanism; |
| - | Formed a research collaboration
with BIND Therapeutics to engineer CD206 targeted nanoparticles using Manocept; |
| - | Reported positive Manocept
proof-of-concept data demonstrating the potential for the Manocept platform as a diagnostic and therapeutic for rheumatologic
conditions; and, |
| - | Received
confirmation of continued NIH-grant funding for clinical trials of NAV4694 in Alzheimer’s Disease and Mild Cognitive Impairment
totaling $1.7 million. |
Financials
Total revenues for the quarter ended June
30, 2015 were $2.9 million compared to $1.1 million in the second quarter of last year. Second quarter 2015 product revenues recognized
from the sale of Lymphoseek were $2.0 million, compared to $1.8 million in the first quarter of 2015 and $1.0 million in the second
quarter of last year. During the second quarter of 2015, the Company also reported $904,000 in grant, licensing and other revenue.
For the six months ended June 30, 2015, Navidea’s total revenue was $5.0 million compared to $1.8 million for the same period
in 2014, an increase of 172%. The primary driver of this increase was revenues recognized from the sale and license of Lymphoseek
which exceeded $4.1 million for the six months ended June 30, 2015 compared to $1.7 million for the same period last year.
Gross margins on Lymphoseek product sales
grew to 83% for the second quarter of 2015 compared to 74% for the second quarter of 2014 due in part to our success in lowering
our manufacturing costs coupled with our ability to sell certain previously reserved inventory.
Research
and development (R&D) expenses for the second quarter of 2015 were $2.3 million, compared to $5.1 million in the second quarter
of last year. R&D expenses were $6.3 million for the six months ended June 30, 2015 compared to $10.3 million in the same period
of 2014. The net decreases in R&D expenses were primarily a result of decreased project costs related to the Company’s
neuro assets coupled with decreased headcount costs. Selling, general and administrative (SG&A) expenses for the second quarter
of 2015 were $4.0 million, compared to $4.9 million in the second quarter of last year. SG&A expenses were $9.5 million for
the six months ended June 30, 2015, compared to $8.8 million for the same period in 2014
and included $765,000 and $1.4 million, respectively,
in termination-related costs associated with reductions in force implemented in the impacted periods.
The net increase in year-to-date SG&A expenses was due primarily to net increases in commercial headcount costs related to
the addition of our internal sales force offset by decreased costs related to contracted medical science liaisons.
Total operating expenses were $6.3 million for the second quarter
of 2015, compared to $10.0 million in the second quarter of last year. Operating expenses were $15.8 million for the six months
ended June 30, 2015, compared to $19.2 million for the same period in 2014.
Navidea’s net loss from operations
for the quarter ended June 30, 2015 was $3.8 million compared to $9.2 million for the same period in 2014. For the six months ended
June 30, 2015, Navidea’s net loss from operations was $11.6 million compared to a net loss from operations of $17.8 million
for the same period in 2014. Navidea’s net loss attributable to common stockholders for the quarter ended June 30, 2015 was
$9.7 million, or $0.06 per share, compared to $10.2 million, or $0.07 per share, for the same period in 2014. For the six months
ended June 30, 2015, Navidea’s net loss attributable to common stockholders was $17.0 million, or $0.11 per share, compared
to a net loss attributable to common stockholders of $22.0 million, or $0.15 per share, for the same period in 2014. Net losses
attributable to common stockholders include the cash interest expense on our outstanding debt, as well as significant non-cash
charges. For the six month periods ended June 30, 2015 and June 30, 2014, net loss attributable to common stockholders included
$3.4 million and $2.7 million, respectively, in non-cash interest, losses on extinguishment of debt, and changes in the fair value
of financial instruments.
NAVIDEA BIOPHARMACEUTICALS
Page | 3
Navidea ended the quarter with $15.8 million
in cash. The Company reiterates its 2015 Lymphoseek product revenue estimate of $10 million to $12 million. The Company also
expects, following completion of the partnering activities for NAV4694, that cash operating expenses on a quarterly basis will
decrease to the point necessary for the Company to achieve its goals of cash flow breakeven from operations. This guidance
excludes therapeutic-related research and development costs for the Manocept platform which are expected to be funded separately
by Macrophage Therapeutics, Inc.
“With each passing quarter, we continue
to take steps towards achieving our goal of cash flow breakeven,” said Brent Larson, Navidea’s EVP and CFO. “We
began this second quarter with a solid refinancing, positioning our balance sheet to support a pivotal second half of the year
in which we expect to realize the impact of our new sales force on Lymphoseek’s revenue growth. This growth, coupled with
continued emphasis on controlling our spending, should put us in a strong position to achieve our goals.”
Commercialization
The new commercialization plan aligns our
sales force to target the oncology treatment team focusing on the surgical oncologist. Initial commercial efforts are being concentrated
in breast cancer, melanoma, and oral cavity head and neck cancers, where sentinel lymph node biopsies are already standard of care.
The Lymphoseek clinical value proposition and its highly differentiated label provide compelling benefits to the oncology treatment
team.
“We achieved our full field force
deployment during the middle of the second quarter, positioning us to ramp up Lymphoseek sales according to plan in the second
half of 2015,” said Thomas Klima, SVP and Chief Commercial Officer. “We are on track with our key performance indicators
including brand revenues, monthly procedure growth, brand awareness and message recall measurements. We are ahead of plan in the
number of accounts purchasing for the first time and in our account product re-order rate. Based on the anticipated impact of the
deployment of our sales force, our positive first half revenues, strong key performance indicators and a planned July 31st
price increase, we remain confident in our ability to meet our 2015 sales projections.”
Manocept Pipeline
Our future business will be dependent on
development of the Manocept CD206 targeting platform for diagnostic and therapeutic applications. Recent Manocept presentations
have reported proof-of-concept localization results in humans and early potential seen in Manocept-drug conjugate delivery resulting
in apoptosis of tumor cells and associated macrophages in a KS pre-clinical study. At recent medical conferences, the company and
its research collaborators reported the following data:
| – | Results were presented
in RA at EULAR 2015 European Congress of Rheumatology which highlighted
the potential of CD206-targeting Manocept constructs to detect immune-mediated inflammation in RA which could be used diagnostically,
to monitor therapeutic efficacy or as a potential therapeutic platform; |
NAVIDEA BIOPHARMACEUTICALS
Page | 4
| – | Data were presented
at the 18th International Workshop on Kaposi’s Sarcoma Herpesvirus and Related Agents demonstrating
the imaging and therapeutic potential for our CD206 targeting platform, Manocept, including inducing apoptosis in KS tumor tissue
and tumor associated macrophages. |
“We continue to build growing evidence
supporting the potential of immunotherapeutic applications for Manocept based on these encouraging results,” said Frederick
O. Cope, Ph.D., SVP and Chief Scientific Officer of Navidea. “Our plans are to continue studies that will validate Lymphoseek’s
ability to identify sites of disease and, through our Macrophage Therapeutics subsidiary, evaluate the modulation and/or destruction
of macrophages and seek lucrative partnering and collaboration agreements to develop promising therapeutic applications.”
Conference Call Details
Investors and the public are invited to
access the live audio webcast through the link below. Participants who would like to ask questions during the question and answer
session must participate by telephone also. Participants are encouraged to log-in and/or dial-in fifteen minutes before the conference
call begins. The webcast replay is expected to be available on our investor website, http://ir.navidea.com,
approximately two to four hours after the live event.
Event: |
Navidea Biopharmaceuticals Q2 2015 Financial Results Conference Call |
|
|
Date/Time: |
Thursday, July 30, 2015 at 8:30 a.m. EDT |
|
|
Webcast Link: |
http://edge.media-server.com/m/p/amn8cqij/lan/en |
|
|
Dial-in Number – US: |
(855) 897-5884 |
|
|
Dial in Number – Int’l: |
(720) 634-2940 |
|
|
Confirmation Number: |
92935833 |
|
|
Replay: |
A webcast replay will be available on the Investor Relations section of our website at http://ir.navidea.com for 30 days. |
About Lymphoseek
Lymphoseek® (technetium
Tc 99m tilmanocept) injection is the first and only FDA-approved receptor-targeted lymphatic mapping agent. It is a novel, receptor-targeted,
small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients. Lymphoseek
is designed for the precise identification of lymph nodes that drain from a primary tumor, which have the highest probability of
harboring cancer. Lymphoseek is approved by the U.S. Food and Drug Administration (FDA) for use in solid tumor cancers where lymphatic
mapping is a component of surgical management and for guiding sentinel lymph node biopsy in patients with clinically node negative
breast cancer, melanoma or squamous cell carcinoma of the oral cavity. Lymphoseek has also received European approval in imaging
and intraoperative detection of sentinel lymph nodes in patients with melanoma, breast cancer or localized squamous cell carcinoma
of the oral cavity.
NAVIDEA BIOPHARMACEUTICALS
Page | 5
Accurate diagnostic evaluation of cancer
is critical, as it guides therapy decisions and determines patient prognosis and risk of recurrence. Overall in the U.S., solid
tumor cancers may represent up to 1.2 million cases per year. The sentinel node label in the U.S. and Europe may address approximately
235,000 new cases of breast cancer, 76,000 new cases of melanoma and 45,000 new cases of head and neck/oral cancer in the U.S.,
and approximately 367,000 new cases of breast cancer, 83,000 new cases of melanoma and 55,000 new cases of head and neck/oral cancer
diagnosed in Europe annually.
Lymphoseek Indication and Important Safety Information
Lymphoseek is a radioactive diagnostic agent indicated with
or without scintigraphic imaging for:
| • | Lymphatic mapping using
a handheld gamma counter to locate lymph nodes draining a primary tumor site in patients with solid tumors for which this procedure
is a component of intraoperative management. |
| • | Guiding sentinel lymph
node biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity,
breast cancer or melanoma. |
Important Safety Information
In clinical trials with Lymphoseek, no
serious hypersensitivity reactions were reported, however Lymphoseek may pose a risk of such reactions due to its chemical similarity
to dextran. Serious hypersensitivity reactions have been associated with dextran and modified forms of dextran (such as iron dextran
drugs).
Prior to the administration of Lymphoseek,
patients should be asked about previous hypersensitivity reactions to drugs, in particular dextran and modified forms of dextran.
Resuscitation equipment and trained personnel should be available at the time of Lymphoseek administration, and patients observed
for signs or symptoms of hypersensitivity following injection.
Any radiation-emitting product may
increase the risk for cancer. Adhere to dose recommendations and ensure safe handling to minimize the risk for excessive
radiation exposure to patients or health care workers. In clinical trials, no patients experienced serious adverse reactions
and the most common adverse reactions were injection site irritation and/or pain (<1%).
FULL LYMPHOSEEK PRESCRIBING INFORMATION CAN BE FOUND AT:
WWW.LYMPHOSEEK.COM
About Navidea
Navidea Biopharmaceuticals,
Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics,
therapeutics and radiopharmaceutical agents. Navidea is developing multiple precision-targeted products and platforms including
Manocept™ and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy,
clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept)
injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe
in November 2014. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical
agents and therapeutics, and advancing the Company’s pipeline through global partnering and commercialization efforts. For
more information, please visit www.navidea.com.
NAVIDEA BIOPHARMACEUTICALS
Page | 6
The Private Securities Litigation Reform
Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in
this news release, which relate to other than strictly historical facts, such as statements about the Company’s plans and
strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and
regulatory pathways, and markets for the Company’s products are forward-looking statements within the meaning of the Act.
The words “believe,” “expect,” “anticipate,” “estimate,” “project,”
and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that
such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated
results due to many factors including, but not limited to, the Company’s continuing operating losses, uncertainty of market
acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital
funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience,
risks of development of new products, regulatory risks and other risks detailed in the Company’s most recent Annual Report
on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise
any forward-looking statements.
Source: Navidea Biopharmaceuticals, Inc.
Contact: Navidea Biopharmaceuticals
Investors
Tom Baker, 617-532-0624
tbaker@navidea.com
Media
Sharon Correia, 978-655-2686
Associate Director, Corporate Communications
FINANCIAL TABLES TO FOLLOW
- ### -
NAVIDEA BIOPHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
| |
June 30, | | |
December 31, | |
| |
2015 | | |
2014 | |
| |
(unaudited) | | |
| |
Assets: | |
| | |
| |
| |
| | |
| |
Cash | |
$ | 15,790,235 | | |
$ | 5,479,006 | |
Other current assets | |
| 3,740,817 | | |
| 3,120,139 | |
Non-current assets | |
| 2,667,537 | | |
| 3,321,035 | |
| |
| | | |
| | |
Total assets | |
$ | 22,198,589 | | |
$ | 11,920,180 | |
| |
| | | |
| | |
| |
| | | |
| | |
Liabilities and stockholders' deficit: | |
| | | |
| | |
| |
| | | |
| | |
Deferred revenue, current | |
$ | 1,000,000 | | |
$ | - | |
Notes payable, net of discount, current | |
| 333,333 | | |
| 4,383,472 | |
Other current liabilities | |
| 4,255,359 | | |
| 4,711,619 | |
Deferred revenue | |
| 666,667 | | |
| - | |
Notes payable, net of discount | |
| 58,836,254 | | |
| 29,539,135 | |
Other liabilities | |
| 1,725,477 | | |
| 3,089,420 | |
Total liabilities | |
| 66,817,090 | | |
| 41,723,646 | |
| |
| | | |
| | |
Navidea stockholders' deficit | |
| (45,088,427 | ) | |
| (29,803,466 | ) |
Noncontrolling interest | |
| 469,926 | | |
| - | |
Total stockholders' deficit | |
| (44,618,501 | ) | |
| (29,803,466 | ) |
| |
| | | |
| | |
Total liabilities and stockholders' deficit | |
$ | 22,198,589 | | |
$ | 11,920,180 | |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| |
Three Months Ended | | |
Six Months Ended | |
| |
June 30, | | |
June 30, | | |
June 30, | | |
June 30, | |
| |
2015 | | |
2014 | | |
2015 | | |
2014 | |
| |
(unaudited) | | |
(unaudited) | | |
(unaudited) | | |
(unaudited) | |
Revenue: | |
| | |
| | |
| | |
| |
Lymphoseek sales revenue | |
$ | 1,963,548 | | |
$ | 1,046,257 | | |
$ | 3,798,970 | | |
$ | 1,672,888 | |
Lymphoseek license revenue | |
| 250,000 | | |
| - | | |
| 333,333 | | |
| - | |
Grant and other revenue | |
| 654,360 | | |
| 28,433 | | |
| 844,061 | | |
| 153,606 | |
Total revenue | |
| 2,867,908 | | |
| 1,074,690 | | |
| 4,976,364 | | |
| 1,826,494 | |
| |
| | | |
| | | |
| | | |
| | |
Cost of goods sold | |
| 332,730 | | |
| 270,498 | | |
| 781,787 | | |
| 463,718 | |
| |
| | | |
| | | |
| | | |
| | |
Gross profit | |
| 2,535,178 | | |
| 804,192 | | |
| 4,194,577 | | |
| 1,362,776 | |
| |
| | | |
| | | |
| | | |
| | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development | |
| 2,297,074 | | |
| 5,112,098 | | |
| 6,278,362 | | |
| 10,338,892 | |
Selling, general and administrative | |
| 4,048,799 | | |
| 4,907,652 | | |
| 9,542,967 | | |
| 8,818,485 | |
Total operating expenses | |
| 6,345,873 | | |
| 10,019,750 | | |
| 15,821,329 | | |
| 19,157,377 | |
| |
| | | |
| | | |
| | | |
| | |
Loss from operations | |
| (3,810,695 | ) | |
| (9,215,558 | ) | |
| (11,626,752 | ) | |
| (17,794,601 | ) |
| |
| | | |
| | | |
| | | |
| | |
Interest expense, net | |
| (1,575,741 | ) | |
| (909,051 | ) | |
| (2,542,317 | ) | |
| (1,846,096 | ) |
Equity in the loss of joint venture | |
| (6,205 | ) | |
| - | | |
| (268,432 | ) | |
| - | |
Change in fair value of financial instruments | |
| (1,852,730 | ) | |
| (92,332 | ) | |
| (125,627 | ) | |
| 300,151 | |
Loss on extinguishment of debt | |
| (2,440,714 | ) | |
| - | | |
| (2,440,714 | ) | |
| (2,610,196 | ) |
Other income (expense), net | |
| (4,834 | ) | |
| (5,293 | ) | |
| 21,698 | | |
| (12,045 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss | |
| (9,690,919 | ) | |
| (10,222,234 | ) | |
| (16,982,144 | ) | |
| (21,962,787 | ) |
Net loss attributable to noncontrolling interest | |
| (387 | ) | |
| - | | |
| (487 | ) | |
| - | |
Deemed dividend on beneficial conversion feature | |
| - | | |
| - | | |
| (46,000 | ) | |
| - | |
| |
| | | |
| | | |
| | | |
| | |
Net loss attributable to common stockholders | |
$ | (9,690,532 | ) | |
$ | (10,222,234 | ) | |
$ | (17,027,657 | ) | |
$ | (21,962,787 | ) |
| |
| | | |
| | | |
| | | |
| | |
Loss per common share (basic and diluted) | |
$ | (0.06 | ) | |
$ | (0.07 | ) | |
$ | (0.11 | ) | |
$ | (0.15 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average shares outstanding | |
| | | |
| | | |
| | | |
| | |
(basic and diluted) | |
| 150,107,148 | | |
| 150,019,939 | | |
| 149,951,603 | | |
| 147,416,111 | |
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From May 2024 to Jun 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Jun 2023 to Jun 2024